Subject Index


Acute hepatic failure, artificial supports
- arteriovenous hemodiafiltration and arteriovenous hemofiltration 33
- blood purification in multiple system organ failure 295 (A)
- CAVH 283 (A), 306 (A), 309 (A)
- CAVH treatment after cardiac surgery 315 (A)
Adolescents, treatment modalities in endstage renal disease 4 AIDS, therapeutic and safety considerations in apheresis procedures 51
- Aluminum -, removal by polymethylmethacrylate membrane 286 (A)
- removal in CAPD after desferrioxamine 297 (A)
- Alveolar gas exchange, isovolemic hemodialysis 41
- Amiodarone, treatment of induced thyreotoxicosis 293 (A)
- Amyloid bone cysts, development in hemodialyzed patients 308 (A)
- Antistaphylococcal vaccination, CAPD 312 (A)
- Apheresis -, familial hypercholesterolemia 298 (A)
- procedures, AIDS 51
Ascites, treatment by dialytic ultrafiltration 252
- Arteriovenous dialysis fistulas, hemodynamic consequences 317 (A)
- Arteriovenous hemodiafiltration combined with arteriovenous hemofiltration 33
- Artificial kidney membranes, cardiopulmonary effects in animal models 155
- Atherosclerosis in maintenance dialysis patients 290 (A)
- Beta-2-microglobulin
  - adsorption on dialysis membranes 284 (A)
  - clearances in CAVH 284 (A)
  - effects of different dialyzers 314 (A)
  - elimination by polyacrylonitrile hemofiltration 279 (A)
  - indicator of biocompatibility 278 (A)
  - kinetics and removal during hemofiltration 275 (A)
  - kinetics during dialysis 307 (A)
  - levels during hemodialysis 311 (A)
  - predisposition to arthropathies in hemofiltration and hemodialysis 306 (A)
  - removal during hemodiafiltration 281 (A)
  - removal during hemofiltration 288 (A), 289 (A)
  - removal by different membranes 279 (A)
  - 281 (A), 286 (A), 289 (A), 305 (A), 316 (A)
  - rise during hemodialysis 285 (A)
- Bicarbonate concentrate, microbial contamination 299 (A)
- Bicarbonate hemodiafiltration, acid-base balance 272 (A)
- Bicarbonate kinetics, paired filtration dialysis
Biofiltration - acetate-free 274 (A) - as alternative to bicarbonate dialysis 319 (A) - continuous computerized monitoring of hemodynamic parameters 318 (A) - mass transfer 282 (A) Blood purification - analysis of membrane processes 202 - hemofiltration, hemodialysis and hemoperfusion in series 297 (A) - in acute renal failure with multiple organ failure 295 (A) - short time techniques 307 (A) - socioeconomic aspects in developing countries 292 (A) Blood purification systems, immobilized enzymes 292 (A) Blood viscosity, erythropoietin treatment 277 (A) Caffeine, hemodynamic effects in chronic renal failure 276 (A) Cancer, double filtration plasmapheresis 287 (A) CAPD - abdominal hernias 312 (A) - aluminum removal after desferrioxamine 297 (A) - antistaphylococcal vaccination 312 (A) - HTLV HI antibody positive patients 308 (A) - interferon-γ and peritoneal macrophages 291 (A) - isolated ultrafiltration in diabetic nephropathy 308 (A) - kanamycin as marker of middle-molecular solute transport 291 (A) - large molecule removal 280 (A) - leukocyte tissue-type plasminogen activator 290 (A) - model of solute transport 316 (A) - peritoneal neutrophilia 312 (A) - positive H+ ion balance 299 (A) - safer connection device 312 (A) - vasopressin secretion 271 (A) Cardiopulmonary bypass, damaging effects 168 Cardiopulmonary effects, membranes 155 Cardiovascular function - isovolemic hemodialysis 41 - ultrafiltration in healthy man 277 (A) Cardiovascular stability, intermittent ultrafiltration 271 (A) Catabolism, hemodialysis 303 (A) Catecholamines, hemodiafiltration 303 (A) CAVH - acute renal failure 309 (A) - acute renal failure after cardiac surgery 315 (A) - functional characteristics of hemofilters 301 (A) - increasing filter life 297 (A) - in vitro hemodynamic evaluation 294 (A) - low molecular weight heparin in children 317 (A) - neonatal treatment 288 (A) - simple device for acute renal failure 306 (A) - suction-supported, in children 318 (A) - treatment of edematous states 279 (A) Children, treatment modalities in endstage renal disease 4 Cholestyramine, bilirubin adsorption 280 (A) Ciclosporin A systemic lupus erythematosus 271 (A) Continuous arteriovenous hemofiltration, see CAPD Chronic ambulatory peritoneal dialysis, see CAVH Cirrhosis, treatment of ascites with a hemofilter system 252 Complement - activation by different membranes 202, 276 (A)
288 (A), 289 (A) -, activation in hemodialysis 289 (A) -, activation in hemofiltration 288 (A) -, activation by plasma exchange and centrifugation technique 311 (A) -, artificial organs 100 -, fragments in hypersensitivity reactions during hemodialysis 292 (A) -, production of interleukin-1 270 (A) Complement split C 3d, extracorporeal circulation

162 Complications, short-term dialysis 193 Computer modelling, hemodialysis 278 (A) Continuous arteriovenous hemodialysis

- -, acute renal failure 283 (A)
- -, beta-2-microglobulin clearances
284 (A) Cryofiltration, prediction of clinical response 14 Cryoglobulinemia, double-filtration plasmapheresis

300 (A) Cuprophan
- -, biocompatibility 262 -, cutaneous hypersensitivity in hemodialyzed patients 315 (A)
Diabetes, hemodialysis 291 (A) Diabetic nephropathy
- -, isolated ultrafiltration combined with CAPD
308 (A)
- -, substitutive treatment in North-Western Italy
314(A) Dialysate, bacterial contamination 284 (A) Dihydrotachysterol, immunity in hemodialyzed patients 303(A) 25-Dihydroxycholecalciferol, immunity in hemodialyzed patients 303 (A)

Edema, continuous arteriovenous hemofiltration 279 (A) Endotoxinemia, bacterial contamination of dialysate 284 (A) Endotoxins
- -, in hemodialysis patients 280 (A) -, transport with high-flux membranes 202 End-stage renal disease, infants, children, adolescents 4 Erythropoietin
- -, blood viscosity after treatment 277 (A) -, treatment of anemia in hemodialyzed patients 309 (A) Ethylene oxide
- -, antibodies in hemodialysis patients 292 (A)
- -, cutaneous hypersensitivity in hemodialyzed patients 315 (A) Extracorporeal circulation, complement activation 162

First-use syndrome
- -, hollow-fiber dialyzers 112
- -, limulus-amebocyte-lysate-reactive material
115 Furosemide, intraperitoneal application in peritoneal dialysis 270(A)

326

Subject Index

Heart failure, treatment by ultrafiltration 309 (A)
Hemofiltration
- -, beta-2-microglobulin removal 281(A)
- -, long-term evaluation 282 (A)
- -, plasma catecholamines and blood purification
303(A) Hemodialysis
amyloid bone cysts 308 (A)
analysis of membrane processes 202
atherosclerosis 290 (A)
autonomous hyperparathyroidism 269 (A)
beta-2-microglobulin levels and removal 279 (A), 281 (A), 311 (A), 314 (A), 316 (A)
blood gases and 2,3-DPG 302(A)
complement activation 100,123,162
computer modelling 278 (A)
continuous computerized monitoring of hemodynamic parameters 318 (A)
cutaneous hypersensitivity to cuprophan and ethylene oxide 315 (A)
density changes and chemotactic receptors of leukocytes 138
depressed natural killer cell function 305 (A) in diabetic patients 291 (A)
double-lumen single needle 273 (A)
early complement activation 289 (A)
endotoxins 280 (A), 284 (A)
ethylene oxid antibodies 291(A)
first-use syndrome 115
homeostat artificial kidney 275 (A)
hypersensitivity reactions 292 (A)
immunoglobulin levels 310(A)
implantable jugular vein catheter 315 (A)
interleukin-1 activity 295 (A)
isovolemic in healthy man 41
jugular vein cannulation 275(A)
limulus-amebocyte-lysate-reactive material 115
lipid peroxidation 296 (A)
long-term complications of short-term treatment 193
mass transfer 272 (A), 282 (A)
microbial contamination of bicarbonate concentrate 299 (A)
neutrophil chemotaxis 24
paired filtration dialysis with two-chamber technique 283 (A)
parenteral nutrition 281(A)
patient’s view 1
phthalate-free tubings 272 (A)
prostaglandins 290 (A)
protein catabolism 269 (A)
racial, sexual and age discrimination 290 (A)
reuse and effective clearance of dialyser 296 (A) in series with hemofiltration and hemoperfusion 297 (A)
- short-time techniques 307 (A)
- somatic and psychosocial prognostic indicators 287 (A)
- sterile dialysate 306 (A) - sterile dialysate and combination with CAPD 273 (A)
thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A) - in Turkey 286 (A)
- urea rebound and hypercatabolism 303 (A) - vena cave inferior diameter and optimal dry weight 293 (A) - very low molecular weight heparin 300 (A), 301 (A) - via a central catheter 304 (A)
Hemofilter reuse, cost, safety, performance 256
Hemofiltration
- analysis of membrane processes 202 - beta-2-microglobulin kinetics and removal 275 (A), 279 (A), 288 (A) - blood gases and 2,3-DPG 302 (A) - complement activation 288 (A)
- hemofilter reuse 256 - in series with hemodialysis and hemoperfusion 297 (A) - patient’s view 1 - thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A) - treatment of cardiovascular complications 294 (A) - urea kinetic modelling 283 (A) - very low-molecular-weight heparin 300 (A), 301 (A) - 9 years experience 302 (A)
Hemoperfusion - in series with hemodialysis and hemofiltration 297 (A) - thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A)
Hemophan, biocompatibility 262
Hemosorption - in end-stage renal failure and after transplantation 301 (A) - parameters of natural resistance 298 (A) - rapidly progressive glomerulonephritis 298 (A) - Homeostat artificial kidney, personalized dialysis 275 (A) - low molecular weight heparin for CAVH in children 317 (A) - side effects of low molecular weight heparin 278 (A) - very low molecular weight heparin in hemodialysis and hemofiltration 300 (A), 301 (A)
Subject Index 327

Hollow-fiber dialyzers, first-use syndrome 112
HTLV III, positive antibodies in CAPD patients 308 (A)
Hypercholesterolemia - LDLapheresis 298 (A) - low-density lipoprotein plasma adsorption 313 (A)
Hyperparathyroidism, in hemodialysis 269 (A)
Immobilized enzymes, blood purification systems 292 (A) Immunoabsorbents, in vitro testing 292 (A) Immunoglobulin, levels in hemodialyzed patients 310 (A) Infants, treatment modalities in end-stage renal disease 4 Interferon-peritonitis in CAPD patients 291 (A) Interleukin-1 - activity in hemodialysis patients 295 (A) - artificial organs 100 - production using different membranes 270 (A) Jugular vein cannulation, hemodialysis 275 (A) Jugular vein catheter, hemodialysis 315 (A) Kanamycin, middle-molecular solute transport in
CAPD 291 (A) Killer cells, function in hemodialyzed patients
305 (A)
Large molecule removal, CAPD 280 (A)
Leukocyte tissue-type plasminogen activator, activity
in CAPD 290 (A) Leukocytes, chemotactic receptors in hemodialysis and
peritoneal dialysis 138, different membranes 276 (A) Limulus-amebocyte-lysate-reactive
material, first-use
syndrome in hemodialysis 115 Lipid peroxidation, in hemodialysis 296 (A) Lipoprotein plasma
adsorption, familial
hypercholesterolemia 313 (A) Lupus nephritis, plasma exchange 304 (A) Lymphocyte
proliferation, immunomodulatory effect
of specific immune complexes 311 (A)
Macrophages, peritonitis in CAPD 291 (A)
Macrosolute charge, sieving coefficient 286 (A)
Malonyldialdehyde, production in platelets 313 (A)
Membrane
-, adsorption of protein 316 (A)
-, cardiopulmonary effects in animal models 155
-, leukocytes, oxygen-free radical and complement
276 (A) -, protein catabolism 269 (A)
Membrane biocompatibility, platelet functionality
268 (A) Membrane plasmapheresis, analysis of membrane
processes 202 Membrane processes, analysis for blood purification
202
Na+K+ pump, nuclear magnetic resonance 274 (A) Neutrophilia, CAPD patients 312 (A)
Neutrophils, chemotaxis after hemodialysis 24 Nuclear magnetic resonance, Na+K+ pump in
uremia 274 (A)
Oxygen-free radical, production by different membranes 276 (A)
Paired filtration dialysis
-, HCO3 kinetics 268 (A)
-, two-chamber technique 283 (A) Parathyroid hormone, bone formation in renal
osteodystrophy with aluminum deposition
277(A) Parenteral nutrition, metabolic changes during
hemodialysis 281 (A) Peritoneal dialysis
-, density changes and chemotactic receptors of
leukocytes 138
-, intraperitoneal furosemide 270 (A)
-, pharmacological modulation of transport
rates 296 (A) Peritonitis, CAPD 291 (A) Phosphate, mass transfer during acetate and
bicarbonate hemodialysis 272 (A) Phthalate-free hemodialysis tubings,
biocompatibility 272 (A) Plasma exchange
-, active lupus nephritis 304 (A)
-, complement activation 311 (A)
-, rapidly progressive glomerulonephritis
274 (A)
- side effects using different substitution solutions 270 (A)
- thrombotic microangiopathy 310(A)

Plasmapheresis
- cancer treatment 287(A)
- cryoglobulinemia 300 (A)
- effects on rejection 285 (A)
- thyroid hormone detoxication 304 (A)
- thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A)

Plate dialyzer, performance and safety of Gambro Lundia 10-5H 287(A)
Platelets
- malonyldialdehyde production 313 (A)
- membrane biocompatibility 268 (A) 328

Subject Index

Polyacrylonitrile, elimination of beta-2-microglobulin 279 (A)
Polyamide membrane, very effective beta-2-microglobulin removal 289 (A)
Polyethylenemethacrylate membrane, aluminum and beta-2-microglobulin removal 286 (A)
Prostaglandins in maintenance dialysis patients 290 (A)
Protein catabolism, sham dialysis with different membranes 269 (A)
Protein A perfusion, basic investigations and first clinical experiences 179
Protein C, uremia 29
Rapidly progressive glomerulonephritis
- hemosorption 298 (A)
- immunosupression and plasma exchange 274 (A)

Rejection, effects of plasmapheresis 285 (A)
Renal osteodystrophy, aluminum stain and parathyroid activity 277 (A)

Short-term dialysis, long-term complications 192
Sieving coefficient, macrosolute charge 286 (A)

Single needle, daily hemodialysis 273 (A)
Somatosensory evoked potentials, first dialysis 269 (A)
Sterile dialysate hemodialysis, combination with CAPD 273 (A)
Substitution solutions, side effects in plasma exchange 270 (A)
Systemic lupus erythematosus, ciclosporin A 271 (A)

Thrombotic microangiopathy, plasma exchange 310(A)
Thyroid hormones
- detoxication by plasmapheresis 304 (A)
- effects of different blood purification methods 293 (A)

Ultrafiltration
- cardiovascular stability 271 (A)
- in healthy man 277 (A)
- treatment of heart failure 309(A)

Urea kinetic modelling, hemofiltration 283 (A)
Uremia, defective protein C 29

Vasopressin, secretion in CAPD patients 271 (A)